{"disease":{"id":"recurrent-squamous-cell-carcinoma-of-the-head-and-neck","name":"recurrent squamous cell carcinoma of the head and neck"},"drugs":{"marketed":[{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02369874","title":"Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":736,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02207530","title":"Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT03620123","title":"A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT02955290","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04815720","title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Vaccinex Inc.","has_results":false},{"nct_id":"NCT07419464","title":"5-Fluorouracil Response and Optimization STudy (The FROST Trial)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03565783","title":"Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":44,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05271604","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"BioAtla, Inc.","has_results":false},{"nct_id":"NCT06868433","title":"TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05726370","title":"Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05057247","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Glenn J. Hanna","has_results":true},{"nct_id":"NCT06580054","title":"Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT04454489","title":"Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true},{"nct_id":"NCT03758781","title":"IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT04576091","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04220775","title":"Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06357858","title":"ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}